T he striatum, a major component of the basal ganglia, plays a critical role in the control of movement. About 95% of striatal neurons are medium-sized spiny neurons that project either directly or indirectly (i.e., via globus pallidus and subthalamic nucleus) to the substantia nigra͞entopeduncular nuclei, the main output structures of the basal ganglia. Based on this anatomical distinction, striatal projection neurons are generally referred to as belonging to the striatonigral (direct) or to the striatopallidal (indirect) pathway (1).
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Medium-sized spiny neurons integrate glutamatergic excitatory inputs from cortex and thalamus with dopaminergic modulatory inputs from the mesencephalon. In the striatum, dopamine activates both D 1 and D 2 subtypes of dopamine receptors. Striatal projection neurons also express high levels of adenosine A 2A receptors, which appear to be located on the striatopallidal neurons of the indirect pathway (2, 3) and interact antagonistically with dopamine D 2 receptors (4) .
Virtually all striatal projection neurons express high levels of the dopamine-and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32; refs. 5-7). cAMP-dependent protein kinase catalyzes phosphorylation of DARPP-32 on a single threonyl residue (corresponding to Thr-34 of the rat sequence), converting it into a potent and selective inhibitor of protein phosphatase-1 (8) . The DARPP-32͞protein phosphatase-1 pathway is involved in regulation of the state of phosphorylation and activity of a large number of phosphoproteins, such as voltage-dependent sodium and calcium channels, the electrogenic pump Na ϩ ,K ϩ -ATPase, and neurotransmitter receptors (9, 10) .
Recent data obtained in vitro by using rat striatal slices showed that stimulation of either dopamine D 1 or adenosine A 2A receptors causes the phosphorylation and activation of DARPP-32 (11) . Moreover, studies performed in striatal slices from rat and mouse showed that activation of D 2 receptors inhibits the increase in DARPP-32 phosphorylation induced by either D 1 receptor or A 2A receptor agonists (12, 13) . Nothing, however, is known about the contribution of dopamine and adenosine receptors to the regulation of the state of phosphorylation of DARPP-32 in intact animals.
In this study, we have established a technique to measure changes in the levels of phosphoproteins in vivo and used it to examine responses to pharmacological treatments or genetic inactivation that alter dopaminergic and purinergic transmission. Our results indicate that, in the intact striatum, blockade of tonic dopamine D 2 receptor activation increases DARPP-32 phosphorylation and that this effect is counteracted by blockade of either adenosine A 2A or dopamine D 1 receptor-mediated transmission.
Materials and Methods
Chemicals. Eticlopride and cocaine were purchased from Research Biochemicals (Natick, MA). SCH 23390 and SCH 58261 were gifts from E. Ongini (Schering-Plough, Milan, Italy). Goat anti-mouse and goat anti-rabbit horseradish peroxidaseconjugated secondary antibodies and a BCA protein detection kit were purchased from Pierce, and an enhanced chemiluminescence (ECL Plus) detection kit was purchased from Amersham Pharmacia.
Experimental Animals. Male C57͞BL6 mice (20-30 g) were obtained from M & B (Ry, Denmark). Mice heterozygous for the invalidated A 2A receptor gene (14) were bred for eight generations on a CD1 background to dilute the genetic background of the embryonic stem cells (R1 line) derived from the 129 mouse strain. Heterozygotes were bred to generate the A 2A receptor knockout mice and their wild-type littermate controls that were used in this study. The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
drugs were used, the mice were killed 15 min after the second injection. The heads of the animals were immediately immersed in liquid nitrogen for 6 s. The brains were then removed, and the striata were rapidly (20 s) excised on an ice-cold surface, sonicated in 750 l of 1% SDS, and boiled for 10 min.
Determination of the Levels of ATP. ATP levels were measured by bioluminescence with the CytoLux kit provided by Wallac Oy (Turku, Finland) in a Wallac luminometer.
Determination of Phosphoproteins. Aliquots (3 l) of the homogenate were used for protein determination. Equal amounts of protein (40 g; containing equal amounts of DARPP-32) from each sample were loaded onto 10% polyacrylamide gels. The proteins were separated by SDS͞PAGE, and transferred to poly(vinylidene difluoride) membranes (Amersham Pharmacia) by the method of Towbin et al. (15) . Phospho[Thr-34]-DARPP-32 was detected by using mAb-23 (1:1,000 dilution; ref. 16) , and phospho[Ser-133]-cAMP response element-binding protein (CREB) was detected by using a commercial polyclonal antibody (Upstate Biotechnology, Lake Placid, NY; 1:2,000 dilution). Antibody binding was revealed by using goat anti-mouse horseradish peroxidase-linked IgG (diluted 1:10,000) for phospho-DARPP-32 or goat anti-rabbit horseradish peroxidase-linked IgG (diluted 1:20,000) for phospho-CREB as well as the enhanced chemiluminescence immunoblotting detection system. In some experiments, a mAb (C24-5a; diluted 1:10,000; ref. 17) generated against DARPP-32, which is not phosphorylation state specific, was used to estimate the total amount of DARPP-32 in wild-type and A 2A receptor knockout mice. Chemiluminescence was detected by autoradiography. Quantification of the phospho-DARPP-32 and phospho-CREB bands was done by densitometry by using National Institutes of Health IMAGE (version 1.52) software.
Validation of Methodology.
A critical prerequisite for the present study was that dephosphorylation during sampling would be low and hence that the level of phosphoproteins measured ex vivo would reflect the in vivo situation. Because degradation of ATP is one of the most rapid dephosphorylation reactions occurring post mortem, in one series of experiments, we determined the levels of ATP in our striatal extracts. We measured 5.72 Ϯ 0.86 mmol of ATP͞g of tissue (n ϭ 12), a value comparable to the values (2.75 Ϯ 0.10 mmol͞g of tissue) determined by using the best available methods of enzymatic inactivation, such as freezeblowing (18) , and considerably higher than the values seen in a freshly prepared brain slice (0.5 mmol͞g of tissue; ref. 19 ). We also tested the effect of eticlopride (0.1 and 0.5 mg͞kg, i.p.) on the phosphorylation of CREB. CREB is phosphorylated on Ser-133 in response to administration of dopamine D 2 receptor antagonists in vivo, and phospho-CREB is very rapidly dephosphorylated post mortem (20) . Using our extraction procedure, we could determine a 2-fold increase in the levels of phospho-CREB after administration of 0.1 or 0.5 mg͞kg (i.p.) of eticlopride (data not shown). Taken together, these results indicate that dephosphorylation is limited during tissue preparation.
Results
Administration of the dopamine D 2 receptor antagonist eticlopride stimulated DARPP-32 phosphorylation in a dosedependent manner (Fig. 1) . A half-maximal increase in the level of phospho-DARPP-32 was reached at a dose of 0.1 mg͞kg, and a maximal increase was reached at a dose of 0.5 mg͞kg.
Previous data showed that, in striatal slices, activation of either dopamine D 1 or adenosine A 2A receptors increased the level of phospho-DARPP-32 (11) . To determine whether DARPP-32 phosphorylation in intact mice is tonically regulated by these receptors, we administered selective antagonists i.p. 5 min before eticlopride. The selective dopamine D 1 receptor antagonist SCH 23390 (0.125 and 0.25 mg͞kg, i.p.) reduced the increase in DARPP-32 phosphorylation caused by the D 2 receptor antagonist (Fig. 2) . Similarly, the selective adenosine A 2A receptor antagonist SCH 58261, used at a dose of 10 mg͞kg and known to block A 2A receptors in vivo, also reduced the increase in DARPP-32 phosphorylation caused by eticlopride (Fig. 3) .
We also tested the ability of eticlopride to stimulate DARPP-32 phosphorylation in mice in which the gene coding for the adenosine A 2A receptor was disrupted by homologous recombination. Eticlopride (0.5 mg͞kg) failed to cause a signifi- cant increase in phospho-DARPP-32 when administered to A 2A receptor knockout mice, in contrast to its effect in wild-type control mice (Fig. 4 A and B) . Interestingly, eticlopride-treated mice heterozygous for the targeted A 2A receptor allele showed a response intermediate to those of the ϩ͞ϩ and Ϫ͞Ϫ mice (Fig.  4 A and B) , indicating the absence of compensatory upregulation of the remaining normal allele. To exclude that the effects observed were due to reduced expression of DARPP-32, the total amounts of DARPP-32 were estimated in the different genotypes after injection of saline or eticlopride. The levels of DARPP-32 were identical in the wild-type and A 2A receptor knockout mice (Fig. 4C) .
When administered alone, neither SCH 23390 nor SCH 58261 caused a statistically significant decrease in DARPP-32 phosphorylation (Figs. 2 and 3) . In contrast, when combined, the two drugs not only completely reversed the stimulation of DARPP-32 phosphorylation induced by eticlopride but also caused a significant decrease in the basal levels of phospho-DARPP-32 (Fig. 5) .
Cocaine, a drug that increases the extracellular concentration of dopamine by interfering with its reuptake, administered at a dose of 15 mg͞kg, i.p., stimulated the phosphorylation of DARPP-32 ( Figs. 6 and 7 ). This effect was abolished by pretreatment with SCH 23390 (Fig. 6) . In contrast, SCH 58261 did not affect the increase in phospho-DARPP-32 caused by cocaine (Fig. 7) .
Discussion
In the present study, we have demonstrated that systemic administration of the D 2 receptor antagonist eticlopride increases the levels of phospho-DARPP-32 in the striatum. These results indicate that, in vivo, DARPP-32 phosphorylation is kept low by tonic activation of dopamine D 2 receptors. Regulation of the state of phosphorylation of DARPP-32 may account for some of the behavioral effects observed after blockade of D 2 receptors. Indeed, recent data have shown that catalepsy induced by raclopride, a selective D 2 receptor antagonist with neuroleptic properties, is strongly attenuated in DARPP-32 knockout mice (9) .
The effect of eticlopride might be explained in either of two, not mutually exclusive ways. Tonic activity at dopamine D 2 receptors might depress the release of dopamine by reducing firing rate or release at the nerve terminals. Hence, blockade of Likewise, changes in the firing rate of striatal projection neurons induced by elevated levels of extracellular dopamine are reversed by SCH 23390 (24, 25) .
Our results indicate that SCH 23390 was more effective in preventing the cocaine-induced increase in DARPP-32 phosphorylation than the increase induced by eticlopride. This difference can be explained by considering the specific cell populations that might be affected by these drugs. The majority of D 1 receptors are expressed in striatonigral neurons of the direct pathway (1, (26) (27) (28) . Cocaine increases DARPP-32 phosphorylation via activation of D 1 receptors and therefore is likely to affect mostly striatonigral neurons. In contrast, as discussed above, the effect of eticlopride is likely to occur (i) via blockade of presynaptic autoreceptors with a resultant increased release of dopamine and (ii) via blockade of postsynaptic D 2 receptors that are located predominantly in striatopallidal neurons (1, 29) . The latter effect would be expected to be relatively insensitive to SCH 23390.
An important conclusion of this study is that, in vivo, a basal, tonic activation of adenosine A 2A receptors is required to generate the increase in DARPP-32 phosphorylation observed during blockade of dopamine D 2 receptors. This requirement is clearly shown by the inability of eticlopride to stimulate DARPP-32 phosphorylation in A 2A receptor knockout mice. In addition, preadministration of the specific A 2A receptor antagonist SCH 58261 markedly reduced the effect of eticlopride.
Adenosine A 2A receptors are enriched in striatopallidal neurons where they are coexpressed with D 2 receptors (2, 3, 30) . The two receptors exert opposite effects on molecular and physiological responses, such as immediate early gene expression, neurotransmitter release, and motor behavior (4) . The opposite regulation exerted by A 2A receptors and D 2 receptors on DARPP-32 phosphorylation could explain some of these mutually antagonistic actions.
Changes in dopaminergic transmission seem to be involved in the pathogenesis of disorders such as Parkinson's disease and schizophrenia. Depletion of striatal dopamine represents the The number of animals per group varied from 9 to 10. ** , P Ͻ 0.01; * , P Ͻ 0.05 vs. control; ‡, P Ͻ 0.001 vs. eticlopride (ANOVA followed by Newman-Keuls test). eticlopride; ‡, P Ͻ 0.001 vs. cocaine (ANOVA followed by Newman-Keuls test). main cause of Parkinson's disease, which is treated by administering L-DOPA often in combination with D 2 receptor agonists. In contrast, neuroleptic drugs that act by blocking dopamine D 2 receptors are used in the treatment of schizophrenia. Previous studies have indicated that an A 2A receptor antagonist exerts beneficial actions when tested in rodent and primate models of Parkinson's disease (31) (32) (33) . On the other hand, A 2A receptor agonists have been proposed to possess antipsychotic-like properties (34, 35) . The ability of A 2A receptors to regulate the state of phosphorylation of DARPP-32 in vivo is compatible with these suggestions that their pharmacological manipulation may be of potential clinical significance in the treatment of dopamine-related disorders.
